期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 22, 期 4, 页码 523-528出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2009.07.003
关键词
acute myeloid leukaemia; AML; cytogenetic; FLT3; gene expression; karyotype; NPM1; prognosis; mutation
类别
Acute myeloid leukaemia (AML) is a complicated, heterogeneous disease and the prognostic factors may be useful in deciding upon appropriate therapy. Cytogenetic testing at diagnosis yields critical prognostic information, but more refinement in prognosis is required. Within cytogenetic subgroups, further important subgroup definitions are possible based on the mutation status and expression analysis of genes such as C-KIT, FLT3, NPM1 and CEBPA, although defining therapies based on such mutations remains controversial. (c) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据